There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ionis Pharmaceuticals (IONS – Research Report) and Maravai Lifesciences Holdings (MRVI – Research Report) with bullish sentiments.
Ionis Pharmaceuticals (IONS)
In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $67.00. The company’s shares closed last Tuesday at $46.28, close to its 52-week high of $47.74.
According to TipRanks.com, Biliouris ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ionis Pharmaceuticals with a $55.43 average price target, a 26.1% upside from current levels. In a report released yesterday, Citi also reiterated a Buy rating on the stock with a $60.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Maravai Lifesciences Holdings (MRVI)
In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Maravai Lifesciences Holdings, with a price target of $17.00. The company’s shares closed last Tuesday at $9.14, close to its 52-week low of $9.09.
According to TipRanks.com, McNamara ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Maravai Lifesciences Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $12.53.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IONS:
